Brokerages forecast that Jazz Pharmaceuticals plc (NASDAQ:JAZZ) will report earnings of $3.67 per share for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Jazz Pharmaceuticals’ earnings. The highest EPS estimate is $4.29 and the lowest is $3.35. Jazz Pharmaceuticals posted earnings per share of $4.00 in the same quarter last year, which suggests a negative year over year growth rate of 8.3%. The business is expected to announce its next earnings results on Tuesday, February 22nd.
According to Zacks, analysts expect that Jazz Pharmaceuticals will report full year earnings of $15.50 per share for the current financial year, with EPS estimates ranging from $14.22 to $15.81. For the next year, analysts anticipate that the firm will post earnings of $17.14 per share, with EPS estimates ranging from $15.27 to $18.16. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Jazz Pharmaceuticals.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, November 9th. The specialty pharmaceutical company reported $4.20 earnings per share for the quarter, topping analysts’ consensus estimates of $2.60 by $1.60. Jazz Pharmaceuticals had a negative net margin of 5.62% and a positive return on equity of 21.43%. The business had revenue of $838.12 million during the quarter, compared to the consensus estimate of $829.98 million. During the same quarter in the prior year, the firm posted $3.86 earnings per share.
NASDAQ JAZZ traded down $0.24 during trading hours on Thursday, reaching $129.31. The company’s stock had a trading volume of 288,927 shares, compared to its average volume of 681,663. The firm has a market capitalization of $7.95 billion, a price-to-earnings ratio of -50.71, a P/E/G ratio of 0.69 and a beta of 0.91. The company’s 50-day moving average is $134.84 and its two-hundred day moving average is $154.25. The company has a debt-to-equity ratio of 1.59, a current ratio of 3.58 and a quick ratio of 2.03. Jazz Pharmaceuticals has a 1-year low of $126.01 and a 1-year high of $189.00.
In other news, CEO Bruce C. Cozadd sold 6,598 shares of the stock in a transaction on Monday, October 4th. The stock was sold at an average price of $129.87, for a total transaction of $856,882.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Kim Sablich sold 2,748 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, November 11th. The shares were sold at an average price of $135.01, for a total transaction of $371,007.48. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,162 shares of company stock valued at $2,146,536. Insiders own 4.30% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in JAZZ. Polaris Capital Management LLC acquired a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at $229,646,000. JPMorgan Chase & Co. grew its position in Jazz Pharmaceuticals by 50.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 2,884,972 shares of the specialty pharmaceutical company’s stock valued at $512,487,000 after acquiring an additional 967,343 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in Jazz Pharmaceuticals during the third quarter worth about $97,566,000. Victory Capital Management Inc. lifted its position in shares of Jazz Pharmaceuticals by 714.9% during the second quarter. Victory Capital Management Inc. now owns 731,707 shares of the specialty pharmaceutical company’s stock worth $129,981,000 after purchasing an additional 641,921 shares in the last quarter. Finally, Farallon Capital Management LLC acquired a new stake in shares of Jazz Pharmaceuticals during the third quarter worth about $74,859,000. Institutional investors own 91.42% of the company’s stock.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca.
Featured Story: What Does Beta Mean In Stock Selection?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.